
Arne Kristian Skulberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3226367/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetics of a new, nasal formulation of naloxone. European Journal of Clinical Pharmacology, 2017, 73, 555-562.	1.9	31
2	REBOARREST, resuscitative endovascular balloon occlusion of the aorta in non-traumatic out-of-hospital cardiac arrest: a study protocol for a randomised, parallel group, clinical multicentre trial. Trials, 2021, 22, 511.	1.6	22
3	Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers. European Journal of Clinical Pharmacology, 2018, 74, 873-883.	1.9	16
4	Pharmacokinetics of a novel, approved, 1.4â€mg intranasal naloxone formulation for reversal of opioid overdose—a randomized controlled trial. Addiction, 2019, 114, 859-867.	3.3	15
5	Ambulance-Attended Opioid Overdoses: An Examination into Overdose Locations and the Role of a Safe Injection Facility. Substance Abuse, 2019, 40, 383-388.	2.3	13
6	Prehospital naloxone administration – what influences choice of dose and route of administration?. BMC Emergency Medicine, 2020, 20, 71.	1.9	10
7	Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a doubleâ€dummy, randomised, controlled trial. Addiction, 2022, 117, 1658-1667.	3.3	9
8	Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil. European Journal of Clinical Pharmacology, 2018, 74, 1547-1553.	1.9	8
9	The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. European Journal of Clinical Pharmacology, 2021, 77, 1901-1908.	1.9	5
10	Intranasal Naloxone Administration. New England Journal of Medicine, 2021, 384, e96.	27.0	1
11	NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use. BMJ Open, 2020, 10, e041556.	1.9	1
12	NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use. BMJ Open, 2020, 10, e041556.	1.9	1
13	Naloxone administration—no balance without titration. Addiction, 2022, 117, 2750-2751.	3.3	1
14	Inhaled nitric oxide as temporary respiratory stabilization in patients with COVID-19 related respiratory failure (INOCOV): Study protocol for a randomized controlled trial. PLoS ONE, 2022, 17, e0268822.	2.5	1
15	Opioid education programs and nasal naloxone rescue kits in Europe. Toxicology Letters, 2017, 280, S43.	0.8	0